🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Italy / NCT06800586
Recruiting Observational

Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects

NCT06800586 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-09-15
Last updated
2025-12-19

Condition(s) studied

COPDLung Cancer (NSCLC)Leukemia

Study summary

This study aims to examine the exposure to atmospheric pollutants in a group of non-smoking patients suffering from lung cancer, chronic obstructive pulmonary disease (COPD), and leukemia. The exposure to atmospheric pollutants will be assessed simultaneously in a group of healthy volunteers. The ultimate goal of the study is to enhance the understanding of the mechanisms by which atmospheric pollutants act, in order to develop new tools that can help halt or at least delay the development of diseases associated with pollution.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: Patient Cohort to be Recruited at the Department of Pneumology and Respiratory Intensive Care, IRCCS AOU of Bologna: * Age ≥ 18 years * Patients with a diagnosis of COPD of any severity (FEV1/FVC \< 0.7 after bronchodilation test) * Non-smokers according to ISS definition: patients who declare having smoked less than 100 cigarettes (5 packs of 20) in their lifetime and are not currently smokers * Signature of informed consent Healthy Volunteer Cohort to be Recruited at the Department of Pneumology and Respiratory Intensive Care, IRCCS AOU of Bologna: * Age ≥ 18 years * Non-smokers according to ISS definition: subjects who declare having smoked less than 100 cigarettes (5 packs of 20) in their lifetime and are not currently smokers * Absence of comorbidities related to the study (COPD, solid tumors, leukemia) in medical history * Workers of the IRCCS AOU of Bologna, S. Orsola Polyclinic * Signature of informed consent Patient Cohort to be Recruited at the Department of Medical Oncology, IRCCS AOU of Bologna: * Age ≥ 18 years * Patients with a diagnosis of lung neoplasm of any histotype and stage * Non-smokers according to ISS definition: patients who declare having smoked less than 100 cigarettes (5 packs of 20) in their lifetime and are not currently smokers * Signature of informed consent Healthy Volunteer Cohort to be Recruited at the Department of Medical Oncology, IRCCS AOU of Bologna: * Age ≥ 18 years * Non-smokers according to ISS definition: subjects who declare having smoked less than 100 cigarettes (5 packs of 20) in their lifetime and are not currently smokers * Absence of comorbidities related to the study (COPD, solid tumors, leukemia) in medical history * Workers of the IRCCS AOU of Bologna, S. Orsola Polyclinic * Signature of informed consent Patient Cohort to be Recruited at the Hematology Department (Hospital-University Company, Policlinico Riuniti di Foggia): * Age ≥ 18 years * Non-smokers according to ISS definition: patients who declare having smoked less than 100 cigarettes (5 packs of 20) in their lifetime and are not currently smokers * Patients with a diagnosis of leukemia of any type * Signature of informed consent Healthy Volunteer Cohort to be Recruited at the Hematology Department (Hospital-University Company, Policlinico Riuniti di Foggia): * Age ≥ 18 years * Non-smokers according to ISS definition: subjects who declare having smoked less than 100 cigarettes (5 packs of 20) in their lifetime and are not currently smokers * Absence of comorbidities related to the study (COPD, solid tumors, leukemia) in medical history * Workers of the Hospital-University Company, Policlinico Riuniti di Foggia * Signature of informed consent Exclusion Criteria: Patient Cohort to be Recruited at the Department of Pneumology and Respiratory Intensive Care, IRCCS AOU of Bologna: * Deficiency of alpha-1 antitrypsin (A1AT) Healthy Volunteer Cohort to be Recruited at the Department of Pneumology and Respiratory Intensive Care, IRCCS AOU of Bologna: * Workers from the Department of Pneumology and Respiratory Intensive Care, IRCCS AOU of Bologna, S. Orsola Polyclinic Patient Cohort to be Recruited at the Department of Medical Oncology, IRCCS AOU of Bologna: * Previous and/or current diagnosis of solid tumors, myelodysplastic syndromes, myeloproliferative neoplasms * Previous and/or current treatment with antineoplastic agents Healthy Volunteer Cohort to be Recruited at the Department of Medical Oncology, IRCCS AOU of Bologna: * Workers from the Department of Medical Oncology, IRCCS AOU of Bologna, S. Orsola Polyclinic Patient Cohort to be Recruited at the Hematology Department (Hospital-University Company, Policlinico Riuniti di Foggia): * Previous diagnosis of solid tumors, myelodysplastic syndromes, myeloproliferative neoplasms * Previous treatment with antineoplastic agents (alkylating agents, hydroxyurea, topoisomerase II inhibitors, lenalidomide) -Presence of pre-existing genetic conditions (Fanconi anemia, ataxia- telangiectasia, Down syndrome, xeroderma pigmentosum, Li-Fraumeni syndrome) * Infection with human immunodeficiency virus (HIV), human T-lymphotropic virus types 1 or 2, or Epstein-Barr virus Healthy Volunteer Cohort to be Recruited at the Hematology Department (Hospital-University Company, Policlinico Riuniti di Foggia): * Workers from the Hematology Department, Hospital-University Company, Policlinico Riuniti di Foggia

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna Bologna Bologna Recruiting
Respiratory and Critical Care Unit, IRCCS Azienda Ospedaliera-Universitaria di Bologna Bologna Bologna Recruiting
Ematology Unit, Azienda Ospedaliero-Universitaria, Policlinico Riuniti di Foggia Foggia Foggia Recruiting

More IRCCS Azienda Ospedaliero-Universitaria di Bologna trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06800586 on ClinicalTrials.gov ↗ ← All trials in Italy